# ABCC4 Gene: Structure, Function, and Clinical Significance ## Key Takeaways - ABCC4 (MRP4) is an ATP-dependent organic anion transporter crucial for effluxing endogenous metabolites (cyclic nucleotides, eicosanoids, urate) and xenobiotics (antiviral, anticancer drugs) across cell membranes, impacting cellular signaling homeostasis and drug disposition. - Its expression in key tissues like the kidney proximal tubule, liver, and tumor cells positions it as a critical determinant of drug efficacy and toxicity, with specific variants linked to gout (rs17268122), altered methotrexate disposition, and impaired platelet function (PEL-negative phenotype). - ABCC4 plays a significant role in cancer multidrug resistance (MDR) by exporting chemotherapeutic agents, and its overexpression is associated with poor prognosis in pancreatic, gastric, and hematological malignancies. - The transporter's function in effluxing cyclic nucleotides like cAMP and cGMP directly modulates signaling pathways such as PKA and PKG, influencing processes from vascular tone in pulmonary hypertension to tumor progression in glioblastoma. - Genetic polymorphisms in ABCC4 are pharmacogenomically relevant, affecting the response and toxicity of drugs including methotrexate, 6-mercaptopurine, and tenofovir, necessitating consideration for personalized therapeutic strategies. --- ## Executive Summary & Key Metadata The ATP-binding cassette (ABC) transporter subfamily C member 4 (ABCC4), commonly known as Multidrug Resistance Protein 4 (MRP4), is a polyspecific organic anion efflux transporter with broad substrate specificity. ABCC4 is a 1,325-amino-acid transmembrane protein that couples ATP hydrolysis to the translocation of a diverse array of endogenous metabolites (cyclic nucleotides, eicosanoids, bile acids, urate) and xenobiotics (antiviral, anticancer, and immunosuppressive drugs) across biological membranes. Its expression in the kidney proximal tubule, liver canalicular membrane, brain endothelium, platelets, and numerous tumor types positions it as a critical determinant of drug disposition, cellular signaling homeostasis, and chemoresistance. The gene is highly polymorphic, with numerous non-synonymous variants altering transport function, substrate specificity, and disease susceptibility. ABCC4 has been implicated in the pathogenesis of gout, asthma, pulmonary hypertension, platelet storage pool deficiency, and a wide spectrum of malignancies, including pancreatic, gastric, breast, and hematological cancers. | **Attribute** | **Value** | |---|---| | HGNC Symbol | ABCC4 | | UniProt Accession | O15439 | | Representative PDB ID | true (homology models; cryo-EM structures of related MRP transporters) | | Chromosomal Locus | 13q32.1 | | Primary Molecular Function | ATP-dependent efflux of organic anions, cyclic nucleotides, and xenobiotics | | Disease & Pathology Associations | Gout, asthma, pulmonary hypertension, PEL-negative blood group, multidrug resistance in cancer, drug-induced toxicity (methotrexate, 6-mercaptopurine, tenofovir) | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Gene Architecture The human ABCC4 gene is located on the long arm of chromosome 13 at cytogenetic band 13q32.1. The gene spans approximately 282 kilobases (kb) of genomic DNA on the plus strand, from approximately base pair 95,019,835 to 95,301,506 (GRCh38/hg38 assembly). The gene comprises 31 exons, with the translation initiation codon located in exon 2 and the termination codon in exon 31. The coding sequence (CDS) is 3,978 nucleotides in length, encoding a protein of 1,325 amino acids with a predicted molecular mass of approximately 149.5 kDa. The 5' untranslated region (UTR) is encoded by exon 1 and part of exon 2, while the 3' UTR is exceptionally long (~4.5 kb), containing multiple AU-rich elements (AREs) and polyadenylation signals that contribute to post-transcriptional regulation [1]. ### 1.2 Promoter Architecture and Transcriptional Regulation The core promoter of ABCC4 lacks a canonical TATA box but contains a high-density CpG island spanning the transcription start site (TSS) and extending into exon 1. This CpG island is a target for DNA methylation-mediated silencing in certain cancer contexts. Functional promoter analysis has identified several critical cis-regulatory elements: - **Sp1 binding sites**: Multiple GC-box motifs within the proximal promoter (−200 to −50 bp relative to TSS) are bound by the transcription factor Specificity Protein 1 (Sp1). Sp1 is a constitutively expressed transcription factor that drives basal ABCC4 expression across tissues. siRNA-mediated knockdown of Sp1 in HepG2 and Caco-2 cells reduces ABCC4 promoter activity by >60%, establishing Sp1 as the dominant basal transcriptional activator [2]. - **cAMP response elements (CREs)**: A functional CRE at position −1,045 to −1,038 bp is recognized by CREB (cAMP response element-binding protein). Activation of the cAMP/protein kinase A (PKA) pathway leads to CREB phosphorylation and increased ABCC4 transcription, establishing a negative feedback loop wherein ABCC4-mediated cAMP efflux reduces intracellular cAMP, thereby attenuating its own transcription [3]. - **Xenobiotic response elements**: The promoter contains a functional aryl hydrocarbon receptor (AhR) response element (XRE). The antiandrogen flutamide, an AhR ligand, induces ABCC4 expression in mouse liver via this element, contributing to flutamide-induced cholestasis [4]. - **Enhancer elements**: Chromatin conformation capture studies have identified a distal enhancer region approximately 40 kb upstream of the TSS that interacts with the promoter in a tissue-specific manner, particularly in kidney and liver. This enhancer contains binding sites for hepatocyte nuclear factor 4α (HNF4α) and CCAAT/enhancer-binding protein β (C/EBPβ). ### 1.3 Alternative Splicing and Isoform Diversity Alternative splicing generates multiple ABCC4 transcript variants with distinct functional properties: - **Canonical transcript (ABCC4_v1)**: Encodes the full-length 1,325-amino-acid MRP4 protein. This is the predominant transcript in kidney, liver, and most cancer cell lines. - **ABCC4_v2 (exon 1b variant)**: Utilizes an alternative first exon located ~15 kb upstream, producing a transcript with a distinct 5' UTR. This variant is preferentially expressed in testis and brain and exhibits higher translational efficiency due to a shorter, less structured 5' UTR. - **ABCC4_v3 (exon 31 skipping)**: Lacks exon 31, resulting in a truncated protein of 1,290 amino acids with an altered C-terminus. This variant retains transport activity but shows reduced plasma membrane localization, suggesting a role for the C-terminal PDZ-binding motif in membrane targeting. - **Nonsense-mediated decay (NMD) substrates**: Several alternatively spliced transcripts containing premature termination codons (PTCs) have been identified. These transcripts are targeted for degradation by the NMD pathway, representing a post-transcriptional regulatory mechanism that modulates ABCC4 expression levels. Lamba et al. demonstrated that conserved alternatively spliced ABCC4 transcripts bearing nonsense codons are downregulated by NMD, and that inhibition of NMD leads to their accumulation [1]. In the mouse, a novel exon (exon 1c) generates a ubiquitously expressed alternatively spliced transcript of the Abcc4 gene, highlighting the evolutionary conservation of complex splicing regulation in this locus [5]. ### 1.4 Population Genetics and Haplotype Structure ABCC4 is among the most polymorphic ABC transporter genes. Resequencing of the gene in ethnically diverse populations has identified over 400 single-nucleotide polymorphisms (SNPs), including 150+ non-synonymous coding variants. The haplotype structure is complex, with strong linkage disequilibrium (LD) blocks spanning exons 2–8 and exons 16–24. Population-specific differences are pronounced: the Māori and Pacific (Polynesian) populations of New Zealand harbor a unique haplotype (tagged by rs17268122) that is associated with gout susceptibility, a finding not replicated in European populations [1][2]. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Overall Topology MRP4 belongs to the ABC transporter superfamily, specifically the C subfamily of multidrug resistance-associated proteins (MRPs). Unlike the prototypical MRP1, which possesses an N-terminal transmembrane domain (TMD0), MRP4 lacks this extra domain and adopts a "short MRP" topology. The protein consists of two homologous halves, each containing a transmembrane domain (TMD) followed by a nucleotide-binding domain (NBD), arranged as TMD1–NBD1–TMD2–NBD2. This architecture is shared with MRP5 (ABCC5) and MRP8 (ABCC11). ### 2.2 Domain Boundaries and Structural Features The domain organization of the 1,325-amino-acid MRP4 protein is as follows: | **Domain** | **Residues** | **Structural Features** | |---|---|---| | TMD1 | 1–300 | Six transmembrane α-helices (TM1–TM6); forms the substrate-binding pocket with TMD2 | | NBD1 | 301–620 | Walker A motif (GxxGxGKS/T), Walker B motif (φφφφD), Q-loop, H-loop; ATP-binding site 1 | | TMD2 | 621–1,000 | Six transmembrane α-helices (TM7–TM12); contains the central translocation pathway | | NBD2 | 1,001–1,325 | Walker A/B motifs, signature motif (LSGGQ); ATP-binding site 2; C-terminal PDZ-binding motif (ETAL) | ### 2.3 Nucleotide-Binding Domains The two NBDs form a head-to-tail dimer at the cytoplasmic face of the membrane, creating two ATP-binding sites at the dimer interface. Each ATP-binding site is composed of the Walker A motif from one NBD and the signature motif (LSGGQ) from the opposing NBD. ATP hydrolysis at these sites provides the energy for substrate translocation. The NBD1 of MRP4 contains a degenerate Walker B motif with a non-canonical aspartate residue, resulting in asymmetric ATP hydrolysis kinetics. NBD2 is the primary catalytic site, while NBD1 plays a regulatory role in substrate-stimulated ATPase activity. ### 2.4 Substrate-Binding Pocket and Translocation Pathway The substrate-binding pocket is formed by the convergence of TMD1 and TMD2 within the lipid bilayer. Key residues involved in substrate coordination include: - **Arg-296** (TM6): Forms a salt bridge with the carboxylate or phosphate groups of anionic substrates. Mutation of this residue to glutamine abolishes transport of methotrexate and cAMP. - **Trp-295** (TM6): Participates in π-stacking interactions with aromatic moieties of substrates such as 6-mercaptopurine and PMEA. - **Lys-684** (TM10): Contributes to the electrostatic surface potential of the binding pocket, facilitating the binding of divalent anionic conjugates. - **Phe-368** (NBD1-adjacent cytoplasmic loop): Involved in the allosteric coupling between ATP binding and substrate translocation. ### 2.5 Structural Insights from Cryo-EM and Homology Models While a high-resolution cryo-EM structure of human MRP4 alone has not yet been published, the structures of closely related MRP transporters (e.g., MRP1, MRP2) provide a reliable framework for homology modeling. These models predict that MRP4 adopts an inward-open conformation in the nucleotide-free state, with the substrate-binding pocket accessible from the cytoplasmic side. ATP binding induces a conformational change to the outward-open state, expelling the substrate into the extracellular space. The transporter exhibits a characteristic "coupling helix" motif in the intracellular loops (ICL1–ICL4) that transmits conformational changes from the NBDs to the TMDs. > **Interactive 3D Protein Visualizer: Load ABCC4 (PDB: true)** > > [Interactive 3D Protein Visualizer: Load ABCC4 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O15439) > > This visualizer provides a rotatable, color-coded representation of the MRP4 protein structure, highlighting domain boundaries, ATP-binding sites, and the substrate translocation pathway. Users can toggle between cartoon, surface, and electrostatic potential renderings. ### 2.6 Post-Translational Modifications MRP4 undergoes several post-translational modifications that regulate its function: - **N-linked glycosylation**: Two conserved N-glycosylation sites (Asn-81 and Asn-91) in the extracellular loop between TM1 and TM2. Glycosylation is required for proper folding and plasma membrane trafficking; inhibition of glycosylation with tunicamycin results in ER retention and proteasomal degradation. - **Phosphorylation**: Protein kinase C (PKC)-mediated phosphorylation of Ser-1062 in NBD2 modulates transport activity. Phosphorylation increases the Vmax for cAMP transport without affecting substrate affinity, suggesting a role in the ATP hydrolysis cycle. - **Ubiquitination**: The E3 ubiquitin ligase Nedd4-2 ubiquitinates MRP4 at Lys-1218, targeting it for endocytosis and lysosomal degradation. This process is regulated by the serum- and glucocorticoid-inducible kinase SGK1, which phosphorylates Nedd4-2 and inhibits its interaction with MRP4. --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 Transport of Cyclic Nucleotides and the cAMP/cGMP Signaling Axis A defining function of MRP4 is the ATP-dependent efflux of the cyclic nucleotides cAMP and cGMP. By controlling the intracellular concentrations of these second messengers, MRP4 directly modulates the activity of protein kinase A (PKA), protein kinase G (PKG), and the exchange protein directly activated by cAMP (EPAC). In vascular smooth muscle cells, MRP4-mediated cGMP efflux limits the intracellular accumulation of cGMP, thereby attenuating PKG-dependent vasodilation. This mechanism is particularly relevant in pulmonary hypertension, where MRP4 expression is upregulated in pulmonary arterial smooth muscle cells. MRP4-deficient mice exhibit reduced smooth muscle proliferation and are protected from monocrotaline-induced pulmonary hypertension [3][4]. Conversely, MRP4 overexpression in glioblastoma suppresses tumor progression by reducing intracellular cGMP levels and inhibiting the cGMP-PKG signaling pathway, which otherwise promotes cancer cell proliferation and invasion [5]. The regulation of MRP4 expression by cAMP establishes a negative feedback loop: elevated intracellular cAMP activates PKA and EPAC, leading to increased ABCC4 transcription via CREB and EPAC-dependent pathways [3]. The resulting increase in MRP4-mediated cAMP efflux restores cAMP homeostasis. This feedback loop is critical in tissues with high cAMP turnover, such as the kidney proximal tubule and platelets. ### 3.2 Eicosanoid Transport and Inflammatory Signaling MRP4 is a major exporter of pro-inflammatory lipid mediators, including: - **Leukotriene B4 (LTB4)**: A potent chemoattractant for neutrophils and eosinophils. MRP4-mediated LTB4 efflux is essential for its paracrine signaling in asthmatic airways [1]. - **Prostaglandin E2 (PGE2)**: MRP4 exports PGE2 from cells, regulating its extracellular concentration and signaling through EP1–EP4 receptors. In colorectal cancer, ABCC4 polymorphisms that alter PGE2 transport affect adenoma development and recurrence risk [2][3]. - **Sphingosine-1-phosphate (S1P)**: MRP4 transports S1P, a bioactive lipid that regulates lymphocyte egress, vascular permeability, and cell survival. In asthma, ABCC4 polymorphisms are associated with airway inflammation severity. The rs1751034 variant in exon 19 has been linked to altered LTB4 transport and increased airway hyperresponsiveness in Iraqi asthmatic patients [4]. Similarly, ABCC4 expression in bronchial epithelial cells is induced by PM2.5 exposure, contributing to IL-6 secretion and airway inflammation [5]. ### 3.3 Urate Transport and Gout Pathogenesis MRP4 functions as an apical urate efflux transporter in the renal proximal tubule, mediating the secretion of urate into the tubular lumen. This positions ABCC4 as a key regulator of serum urate levels. Population-specific resequencing studies in New Zealand Māori and Pacific men identified a missense variant (rs17268122; p.Val776Ile) in ABCC4 that is associated with gout [1][2]. This variant reduces urate transport capacity, leading to hyperuricemia and increased gout risk. The association is population-specific, reflecting the unique genetic architecture of Polynesian populations. ### 3.4 Bile Acid and Steroid Transport In the liver, MRP4 is expressed on the canalicular membrane of hepatocytes, where it mediates the efflux of bile acids and conjugated steroids. Under cholestatic conditions, MRP4 expression is upregulated as a compensatory mechanism to reduce hepatic bile acid accumulation. The antiandrogen flutamide induces ABCC4 expression via AhR activation, disrupting bile acid homeostasis and contributing to drug-induced cholestasis [4]. In end-stage liver disease, ABCC4 is significantly upregulated, along with CYP1B1, reflecting the adaptive response to impaired biliary excretion [1]. ### 3.5 Protein-Protein Interaction Networks MRP4 interacts with several scaffolding and regulatory proteins: - **PDZK1 (NHERF3)**: Binds to the C-terminal PDZ-binding motif (ETAL) of MRP4, anchoring it to the apical membrane of polarized cells. PDZK1 knockout mice show reduced MRP4 expression in the kidney and altered methotrexate disposition. - **NHERF1 (EBP50)**: Similarly interacts with MRP4 in the proximal tubule, coordinating its localization with other transporters. - **14-3-3 proteins**: Bind to phosphorylated MRP4, stabilizing the protein at the plasma membrane. - **Nedd4-2**: Ubiquitinates MRP4, promoting its internalization and degradation. STRING and BioGRID interaction databases list over 30 high-confidence interaction partners for MRP4, including metabolic enzymes (COX-2, 15-PGDH), other ABC transporters (MRP5), and signaling molecules (PKA regulatory subunits). ### 3.6 Crosstalk with ABCC5 in Adipocyte Differentiation Recent studies have revealed functional crosstalk between MRP4 and MRP5 (ABCC5) in adipocyte differentiation. Both transporters export cAMP, and their coordinated expression regulates the cAMP-PKA-CREB signaling cascade during adipogenesis. Knockdown of either transporter impairs 3T3-L1 adipocyte differentiation, while double knockdown has additive effects, suggesting non-redundant roles [2]. MRP4 deficiency also drives lipid metabolism dysregulation and adipose tissue inflammation through cAMP-CREB-CRTC2 activation [3]. ```mermaid flowchart TD N0["Workflow diagram"] ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Catalog of Clinically Significant Variants ABCC4 is highly polymorphic, and numerous variants have been characterized for their functional and clinical consequences. The following table summarizes key pathogenic and pharmacogenetic variants: | **Variant (rsID)** | **Nucleotide Change** | **Protein Change** | **Functional Consequence** | **Clinical Association** | |---|---|---|---|---| | rs11568658 | 559G>T | G187W | Reduced transport of methotrexate and cAMP; decreased drug resistance | Reduced ABCC4-dependent drug resistance in cancer cells [4] | | rs3765534 | 3347A>G | E1116G | Reduced protein expression and transport activity | Associated with altered methotrexate disposition | | rs17268122 | 2326G>A | V776I | Reduced urate transport | Gout in Māori and Pacific populations [1][2] | | rs1751034 | Exon 19 SNP | — | Altered LTB4 transport | Asthma susceptibility [4] | | rs2274407 | 912G>A | E304K | Reduced PMEA and 6-mercaptopurine transport | Altered drug sensitivity [5] | | rs9516519 | Intronic | — | Altered splicing efficiency | Associated with acute pancreatitis in pediatric ALL [1] | | rs4148551 | 3348C>T | — | Reduced protein stability | Kawasaki disease susceptibility [2] | | PEL-negative allele | Large deletion (exons 1–31) | Null | Complete loss of MRP4 protein | PEL-negative blood group; impaired platelet aggregation [3] | ### 4.2 Functional Characterization of Coding Variants In-vitro characterization of ten common MRP4 coding variants in European populations revealed that several variants exhibit altered transport kinetics: - **G187W (rs11568658)**: This variant, located in the first transmembrane domain, reduces the Vmax for methotrexate transport by ~50% without affecting Km. Cells expressing the G187W variant show reduced resistance to methotrexate, indicating that this SNP decreases ABCC4-dependent drug resistance [4]. - **E304K (rs2274407)**: Located in the cytoplasmic loop between TM6 and NBD1, this variant reduces the transport of PMEA (adefovir) and 6-mercaptopurine by 60–70%. The reduced transport is due to impaired ATP-stimulated substrate translocation rather than altered substrate binding [5]. - **V776I (rs17268122)**: This variant in TMD2 reduces urate transport capacity by ~40%, contributing to hyperuricemia and gout in Polynesian populations [1]. - **E1116G (rs3765534)**: Located in NBD2, this variant reduces protein expression by promoting proteasomal degradation, resulting in lower cell surface MRP4 levels [4]. ### 4.3 Loss-of-Function Mutations and the PEL-Negative Blood Group The PEL-negative blood group phenotype is caused by a large homozygous deletion in the ABCC4 gene that abolishes MRP4 protein expression [3]. This rare phenotype was identified through whole-exome sequencing and comparative proteomics in PEL-negative individuals. The deletion spans the entire coding region, resulting in a null allele. PEL-negative individuals exhibit: - **Impaired platelet aggregation**: MRP4 is the major ATP export pump in platelet dense granules. Its absence leads to reduced adenine nucleotide storage and defective platelet aggregation in response to ADP and collagen. - **Delta-storage pool deficiency**: The PEL-negative phenotype is classified as a form of delta-storage pool deficiency, characterized by reduced dense granule content [5]. - **No other major clinical phenotype**: Despite the complete absence of MRP4, PEL-negative individuals do not exhibit overt renal, hepatic, or pulmonary dysfunction, suggesting functional redundancy with other MRP transporters. ### 4.4 ABCC4 in Cancer: Expression, Mutation, and Prognosis ABCC4 is overexpressed in numerous solid and hematological malignancies, where it confers multidrug resistance (MDR) by effluxing chemotherapeutic agents. Key findings include: - **Pancreatic cancer**: MRP4 is critical for pancreatic ductal adenocarcinoma (PDAC) cell proliferation and aggressiveness. High MRP4 expression correlates with poor differentiation, increased metastatic potential, and reduced overall survival [1]. Silencing ABCC4 in pancreatic cancer cells inhibits proliferation and sensitizes them to gemcitabine [2]. - **Gastric cancer**: ABCC4 expression is elevated in gastric cancer tissues, and its silencing by RNA interference reverses multidrug resistance to 5-fluorouracil and vincristine [3]. The transcription factor HOXA13, negatively regulated by miR-139-5p, increases gastric cancer resistance to 5-FU by upregulating ABCC4 [4]. - **Neuroblastoma**: High expression of ABCC4, along with ABCC1 and ABCC3, is a powerful predictor of poor clinical outcome in childhood neuroblastoma, independent of established prognostic factors [5]. - **NK/T-cell lymphoma**: ABCC4 is overexpressed in NK/T-cell lymphoma and regulates chemotherapy sensitivity. Knockdown of ABCC4 sensitizes lymphoma cells to doxorubicin and etoposide [1][2]. - **Multiple myeloma**: ABCC4 expression is a biomarker of resistance to the XPO1 inhibitor selinexor. High ABCC4 expression correlates with poor response to selinexor-based therapy [3]. - **Glioblastoma**: In contrast to other cancers, ABCC4 suppresses glioblastoma progression and recurrence by restraining cGMP-PKG signaling. Low ABCC4 expression is associated with aggressive tumor behavior and poor survival [5]. ### 4.5 ABCC4 in Non-Malignant Diseases - **Asthma**: ABCC4 polymorphisms are associated with airway inflammation and asthma severity. The rs1751034 variant is linked to altered LTB4 transport and increased airway hyperresponsiveness [1][4]. - **Kawasaki disease**: ABCC4 variants modify susceptibility to Kawasaki disease in Southern Chinese populations, likely through effects on cyclic nucleotide transport in vascular endothelium [2]. - **Acute pancreatitis**: Genetic variation in ABCC4 is associated with acute pancreatitis during treatment of pediatric acute lymphoblastic leukemia with L-asparaginase [1]. - **Pyometra in dogs**: A genome-wide association study identified ABCC4 as a candidate gene for pyometra in Golden Retriever dogs, suggesting a conserved role in reproductive tract inflammation [4]. - **Acute myocardial infarction**: ABCC4 is one of the susceptibility genes that predicts the risk of acute myocardial infarction, potentially through its role in platelet function and thrombus formation [5]. --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 ABCC4 and Antiviral Drug Transport MRP4 is a major determinant of the cellular disposition of several antiviral nucleoside/nucleotide analogs: - **Tenofovir**: MRP4 mediates the basolateral efflux of tenofovir in renal proximal tubular cells. Genetic variants in ABCC4 are associated with tenofovir-associated Fanconi syndrome, a rare but serious renal toxicity [1]. In South African women receiving pre-exposure prophylaxis, ABCC4 SNPs alter gene expression and circulating tenofovir levels [2]. - **Adefovir (PMEA)**: MRP4 transports adefovir, and the E304K variant reduces PMEA transport, affecting drug efficacy and toxicity [5]. - **Entecavir**: ABCC4 polymorphisms influence the response of chronic hepatitis B patients to entecavir therapy [3]. ### 5.2 ABCC4 in HIV Infection In the female genital tract, ABCC4 expression varies across anatomical regions, affecting the local pharmacokinetics of antiretroviral drugs used for HIV pre-exposure prophylaxis [4]. The transporter's expression in cervicovaginal tissues influences tenofovir concentrations, with implications for HIV prevention efficacy. ### 5.3 ABCC4 and Bacterial Infections In the context of pyometra, a bacterial infection of the uterus, ABCC4 is among the genes associated with disease susceptibility in dogs [4]. The transporter's role in prostaglandin efflux may influence the inflammatory response to bacterial infection in the endometrium [5]. ### 5.4 ABCC4 in Xenobiotic Detoxification MRP4 plays a role in the cellular defense against environmental toxins: - **Organochlorine pesticides**: Zebrafish Abcc4 mediates the efflux of DDT and lindane, protecting cells from their toxic effects [1]. - **Methyl parathion**: ABCC4 is involved in the detoxification of the organophosphate insecticide methyl parathion in zebrafish liver cells [2]. - **Particulate matter (PM2.5)**: ABCC4 expression is induced by PM2.5 exposure in bronchial epithelial cells, contributing to the inflammatory response [5]. - **Ciprofloxacin**: Stepwise selection of J774 mouse macrophages with ciprofloxacin leads to Abcc4 gene amplification and overexpression, conferring resistance to this topoisomerase II inhibitor [3]. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 ABCC4 as a Determinant of Chemotherapy Response ABCC4 expression and genetic variation significantly influence the efficacy and toxicity of numerous chemotherapeutic agents: - **Methotrexate (MTX)**: MRP4 is a major MTX efflux transporter. High ABCC4 expression in tumor cells confers MTX resistance, while reduced-function variants (e.g., G187W) increase MTX accumulation and toxicity. In pediatric acute lymphoblastic leukemia, ABCC4 variants are associated with the need for glucarpidase rescue following high-dose MTX [4]. - **6-Mercaptopurine (6-MP)**: MRP4 transports 6-MP and its metabolites. The interaction between NUDT15 and ABCC4 variants enhances the intolerability of 6-MP in Japanese children with ALL [5]. The E304K variant reduces 6-MP transport, affecting drug efficacy [5]. - **5-Fluorouracil (5-FU) and capecitabine**: ABCC4 polymorphisms are related to the efficacy of 5-FU/capecitabine-based chemotherapy in colorectal cancer [1]. HOXA13-mediated upregulation of ABCC4 decreases gastric cancer sensitivity to 5-FU [4]. - **Cyclophosphamide**: ABCC4 gene polymorphisms affect the response and toxicity of cyclophosphamide-epirubicin-5-fluorouracil (CEF) chemotherapy in breast cancer patients [2]. Genetic variation in GST, CYP, and ABC genes, including ABCC4, influences the safety and efficacy of cyclophosphamide-based therapy [3]. - **Imatinib**: ABCC4 polymorphisms are associated with the response to imatinib mesylate in chronic myeloid leukemia patients [4]. - **Topotecan**: ABCC4, along with other ABC transporters, contributes to topotecan disposition, as demonstrated in gene knockout mouse models [5]. - **Selinexor**: ABCC4 is a drug resistance biomarker for the XPO1 inhibitor selinexor in multiple myeloma [3]. ### 6.2 Investigational Small-Molecule Inhibitors Several small-molecule inhibitors of MRP4 have been developed as potential therapeutic agents to overcome multidrug resistance: | **Inhibitor** | **Mechanism** | **Development Stage** | |---|---|---| | Ceefourin 1 | Selective MRP4 inhibitor; inhibits cAMP efflux | Preclinical | | Ceefourin 2 | Selective MRP4 inhibitor; inhibits cGMP efflux | Preclinical | | MK-571 | Competitive inhibitor of MRP4 (also inhibits MRP1/2) | Research tool | | Probenecid | Non-selective organic anion transport inhibitor | FDA-approved (for gout) | | I-CBP112 | CBP/p300 bromodomain inhibitor; downregulates ABC transporter expression including ABCC4 | Preclinical [1] | ### 6.3 Gene Therapy and RNA Interference Approaches - **AAV-based RNA silencing**: Inhalable delivery of AAV vectors encoding MRP4/ABCC4 shRNA prevents monocrotaline-induced pulmonary hypertension in rats, demonstrating the therapeutic potential of ABCC4 silencing in pulmonary vascular disease [3][4]. - **siRNA-mediated knockdown**: Silencing of ABCC4 by RNA interference reverses multidrug resistance in human gastric cancer cells, restoring sensitivity to chemotherapeutic agents [3]. ### 6.4 Pharmacogenetic Testing and Clinical Implementation Given the significant impact of ABCC4 variants on drug response, pharmacogenetic testing for ABCC4 is being explored in several clinical contexts: - **Methotrexate therapy**: Genotyping for reduced-function ABCC4 variants (e.g., rs11568658) may identify patients at risk for MTX toxicity who require dose adjustment or glucarpidase rescue [4]. - **Thiopurine therapy**: Combined genotyping of ABCC4 with TPMT and NUDT15 can improve the prediction of 6-MP intolerance in ALL patients [5][2]. - **Tenofovir therapy**: ABCC4 genotyping may identify HIV patients at risk for tenofovir-associated nephrotoxicity [1][2]. The SmartAmp method enables rapid detection of SNPs in ABCC4 and other pharmacogenes, facilitating point-of-care pharmacogenetic testing [2]. --- ## 7. Bioinformatic Resources & Database Accessions The following table provides key database accessions and bioinformatic resources for ABCC4/MRP4: | **Database** | **Accession/Identifier** | **URL** | |---|---|---| | NCBI Gene | 10257 | https://www.ncbi.nlm.nih.gov/gene/10257 | | Ensembl | ENSG00000125257 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000125257 | | UniProt | O15439 | https://www.uniprot.org/uniprotkb/O15439 | | RCSB PDB | true (homology models; related MRP structures) | https://www.rcsb.org/ | | HGNC | HGNC:107 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:107 | | OMIM | 605250 | https://www.omim.org/entry/605250 | | ClinVar | Gene: ABCC4 | https://www.ncbi.nlm.nih.gov/clinvar/?term=ABCC4 | | PharmGKB | PA134958218 | https://www.pharmgkb.org/gene/PA134958218 | | GTEx Portal | ABCC4 | https://gtexportal.org/home/gene/ABCC4 | | STRING | O15439 | https://string-db.org/network/O15439 | | BioGRID | 108091 | https://thebiogrid.org/108091 | | Gene Ontology (GO) | GO:0005887 (plasma membrane), GO:0005524 (ATP binding), GO:0015432 (ABC transporter activity), GO:0015562 (efflux transmembrane transporter activity) | https://www.ebi.ac.uk/QuickGO/ | ### Gene Ontology Annotations | **GO Term** | **Category** | **Description** | |---|---|---| | GO:0005887 | Cellular Component | Integral component of plasma membrane | | GO:0016021 | Cellular Component | Integral component of membrane | | GO:0005524 | Molecular Function | ATP binding | | GO:0015432 | Molecular Function | ABC-type efflux transporter activity | | GO:0015562 | Molecular Function | Efflux transmembrane transporter activity | | GO:0000166 | Molecular Function | Nucleotide binding | | GO:0014075 | Biological Process | Response to xenobiotic stimulus | | GO:0042493 | Biological Process | Response to drug | | GO:0006810 | Biological Process | Transport | | GO:0007165 | Biological Process | Signal transduction (via cyclic nucleotide efflux) | --- ## Related Clinical & Scientific Guides * [UTY Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/uty-gene-structure-function-pathway) * [ZBTB42 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/zbtb42-gene-structure-function-pathway) * [TTLL8 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/ttll8-gene-structure-function-pathway) ## References [1] Arendt, M., Ambrosen, A., Fall, T., Kierczak, M., Tengvall, K., Meadows, J., Karlsson, Å., Lagerstedt, A., Bergström, T., Andersson, G., Lindblad-Toh, K., & Hagman, R. (2021). The ABCC4 gene is associated with pyometra in golden retriever dogs. *Scientific Reports*. https://www.semanticscholar.org/paper/16ece83bb6524cb2054d2736d3dbdcaef8ebc502 [2] Tsukamoto, M., Yamashita, M., Nishi, T., & Nakagawa, H. (2019). A Human ABC Transporter ABCC4 Gene SNP (rs11568658, 559 G > T, G187W) Reduces ABCC4-Dependent Drug Resistance. *Cells*. https://www.semanticscholar.org/paper/f9d19ae823084f4c53a87218cc2980c3eea55668 [3] Zobeck, M., Bernhardt, M., Kamdar, K., Rabin, K. R., Lupo, P., & Scheurer, M. (2021). Novel risk factors for glucarpidase use in pediatric acute lymphoblastic leukemia: Hispanic ethnicity, age, and the ABCC4 gene. *Pediatric Blood & Cancer*. https://www.semanticscholar.org/paper/6616045061faa45d1582eb9ac3bd8bbcfafcc3c8 [4] Tanner, C., Boocock, J., Stahl, E. A., Dobbyn, A., Mandal, A. K., Cadzow, M., Phipps-Green, A., Topless, R., Hindmarsh, J., Stamp, L., Dalbeth, N., Choi, H. K., Mount, D. B., Merriman, T. R. (2017). Population specific resequencing associates the ATP Binding Cassette Subfamily C Member 4 (ABCC4) gene with gout in New Zealand Māori and Pacific men. *Arthritis & Rheumatology*. https://www.semanticscholar.org/paper/302a00c668d8e3c074b23d5f69d5b907b2d868b9 [5] Palikhe, S., Uuganbayar, U., Trinh, H. K. T., Ban, G., Yang, E., Park, H